Sorafenib-induced cardiovascular toxicity: A cause for concern
Authors:
- 29 January 2025
- journal article
- review article
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 410, 111388
Abstract
No abstract availableKeywords
Funding Information
- Hunan Provincial Natural Science Foundation
- National Natural Science Foundation of China
This publication has 74 references indexed in Scilit:
- Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenibInternal and Emergency Medicine, 2024
- Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trialsJournal of Cancer Research and Clinical Oncology, 2021
- Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor SorafenibCardiovascular Toxicology, 2018
- Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled TrialsClinical Drug Investigation, 2018
- Tyrosine Kinase Inhibitor-Induced HypertensionCurrent Oncology Reports, 2018
- Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathwayCancer, 2014
- Risk of venous thromboembolic events associated with VEGFR‐TKIs: A systematic review and meta‐analysisInternational Journal of Cancer, 2012
- Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertensionAngiogenesis, 2012
- Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor SorafenibCardiovascular Toxicology, 2009
- Beneficial Effect of Taurine Treatment Against Doxorubicin-Induced Cardiotoxicity in Mice2009